LEXINGTON, Mass.--(BUSINESS WIRE)--Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that preclinical data presented at the annual meeting of the American Association for Cancer Research (AACR) shows that STA-9090, a novel, synthetic inhibitor of heat shock protein 90 (Hsp90), demonstrated greater activity in lung cancer cells when compared to the 17-AAG class of Hsp90 inhibitors, the class most advanced in the clinic.
